Revolutions Medical has received contract from the US Department of Defense HIV/AIDSPrevention Program (DHAPP) for multiple countries for its proprietary 3cc RevVac Safety Syringe.

Recently, Revolutions Medical has signed letter of intent (LOI) with Medical Investment Group (MIG) for manufacturing the RevVac 3cc safety syringe.

Under the terms of agreement, manufacturing of 5 million syringes per month is expected.

The agreed upon general terms allows an increase of up to 20 million syringes per month through MIG’s both domestic and international manufacturing capabilities.

Revolutions Medical is a safety medical device and software application company and its products include RevVac safety syringe (FDA approved), safety blood drawing device and safety IV catheter.